Phase 4: testing Dapagliflozin for ACS (Acute Coronary Syndrome)
The aim of this clinical trial is to see if dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome. Coronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.
Official registry: https://clinicaltrials.gov/study/NCT07351643 · Shenyang Northern Hospital · enrollment listed as 110
What this phase means
Phase 4: the treatment is already approved. This study asks new questions — longer-term effects, other diseases, or how it compares in everyday care.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Dapagliflozin. The registry lists allocation as randomized. The aim of this clinical trial is to see if dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome.
They plan to enroll about 110 people at Shenyang. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Assessment of the Effects of SGLT2 Inhibitors on Pericoronary Fat in Patients With Stage 4 CKM Syndrome Using Photon-counting CT
Interventions: Dapagliflozin
Primary outcome (registry wording): Changes in FAI from baseline to 6 months in patients assessed by CCTA
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Aged ≥ 18 years, irrespective of gender;
- Meeting the diagnostic criteria for stage 4 CKM syndrome;
- Able to cooperate with photon-counting CT examination during the index hospitalisation, with no contraindications to the examination;
Who the registry excludes
- Receiving SGLT2 inhibitor therapy within 4 weeks prior to enrolment;
- Severe hepatic dysfunction (Child-Pugh class C);
- History of recurrent urogenital tract infections;
- History of allergy or intolerance to SGLT2 inhibitors;
- Pregnant or lactating women;
- Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg;
- Severe chronic kidney disease (eGFR \< 30 mL/min/1.73 m²);
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
1 listed- General Hospital of Northern Theater Command — Shenyang, Liaoning, China (recruiting)
FAQ about this NCT record
Is NCT07351643 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07351643?
Phase 4. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07351643?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary